Oncology Central

High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?

0

Immunotherapy for the treatment of cancer holds the unique promise of durable, systemic antitumor responses capable of targeting malignant disease throughout the body. Just 8 years after the discovery of IL-2 [1], this promise was first fulfilled in a small clinical trial utilizing systemic high-dose IL-2 (HD IL-2) demonstrating a complete response in a metastatic melanoma patient who was cured of all malignant disease and has remained disease free for more than 29 years [2,3].

To view restricted content, please:
Share:

Leave A Comment